# US 2004/0204407 A1 · 5-sulfonamido-substituted indolinone compounds as protein kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0204407 A1
- Document ID: US20040204407A1
- Status: Published application
- Kind: A1
- Application number: 10/793,952
- Filed: 2004-03-08
- Published: 2004-10-14
- Earliest claimed: 2003-03-07
- Assignees: Sugen, Inc.
- Inventors: Peng Cho Tang; Congxin Liang; Todd Miller; Kenneth E. Lipson
- Web page: https://patentgrep.com/patent/US20040204407A1

## CPC

- C07D 401/14: containing three or more hetero rings
- C07D 209/34: in position 2
- C07D 403/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 403/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention relates to 5-sulfonamido substituted indolinones that modulate the activity of protein kinases (“PKs”). The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

## Claims

### Claim 1

The compound of Formula (I):
139
wherein
R1 and R2 combine to form an optionally fused heterocyclic ring, which is optionally substituted by —O-alkyl, Br, Cl or F;
R3, R4 and R5 are independently selected from the group consisting of H, lower alkyl optionally substituted with hydroxy and —(Y)0-1—Y1, wherein at least one of R3, R4 or R5 is —(Y)0-1—Y1;
or R3 and R4 may combine to form a cyclic 6-membered alicyclic ring which may be substituted with one or more lower alkyl;
Y is —CH2—, —CH2—CH2—, —CH2—CH2—CH2— or —C(O)NHR6—;
Y1 is —C(O)OR′, —C(O)NR6R7 or —NR6R7, where R′ is H or lower alkyl;
R6 and R7 are independently selected from the group consisting of H and lower alkyl optionally substituted by —NR8R9;
or R6 and R7 may combine to form a heterocyclic ring which may include an additional heteroatom selected from the group consisting of N, O and S and which may be further substituted by optionally substituted alkyl or hydroxy;
R8 and R9 are independently H and lower alkyl;
or R8 and R9 may combine to form a heterocyclic ring which may include an additional heteroatom selected from the group consisting of N, O and S, which may be further substituted by alkyl;
and pharmaceutically acceptable salts thereof.

### Claim 2

A compound selected from the group consisting of Formula IV and VI:
140
wherein
R10-R11 are independently selected from the group consisting of H, lower alkyl, phenyl substituted with halo, thiazolyl and cycloalkyl;
R12 is selected from the group consisting of —CH2—C(O)—X′—(CH2)n—Z, —CH2—Z,
141
where D is O or N—CH3;
X′ is NH, S, O or a bond;
Z is a polar group selected from the group consisting of —C(O)OR13, —C(O)NR13R14, amino, alkylamino, dialkylamino, piperazinyl, pyrrolidinyl and morpholinyl, Z may be further substituted by —(CH2)0-1—Z1, where Z1 is a polar group selected from the group consisting of —C(O)OR13, —C(O)NR13R14, amino, alkylamino, dialkylamino, hydroxy, piperazinyl, pyrrolidinyl and morpholinyl; when Z is further substituted, R13 is not present;
R13 and R14 are independently H and lower alkyl;
n is 0-3; and
Alk is lower alkyl of 1-4 carbons;
and pharmaceutically acceptable salts thereof.

### Claim 3

A compound selected from the group consisting of
5-(2,3-Dihydro-indole-1-sulfonyl)-3-[1-[3,5-dimethyl-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one;
2-{5-[5-[(3-Chloro-phenyl)-methyl-sulfamoyl]-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrol-3-yl}-N-(2-diethylamino-ethyl)-acetamide;
3-[1-[3-(2-Hydroxy-ethyl)-4-(4-methyl-piperazine-1-carbonyl)-1H-pyrrol-2-yl]-meth-(Z)-ylidene]-5-(5-methoxy-2,3-dihydro-indole-1-sulfonyl)-1,3-dihydro-indol-2-one;
5-[5-(5-Methoxy-2,3-dihydro-indole-1-sulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide;
5-[5-(2,3-Dihydro-indole-1-sulfonyl)-2-oxo-1,2-dihydro-indol-(3Z)-ylidenemethyl]-2-methyl-4-[3-(4-methyl-piperazin-1-yl)-propyl]-1H-pyrrole-3-carboxylic acid ethyl ester;
5-(2,3-Dihydro-indole-1-sulfonyl)-3-[1-[3-(3-morpholin-4-yl-propyl)-4,5,6,7-tetrahydro-1H-indol-2-yl]-meth-(Z)-ylidene]-1,3-dihydro-indol-2-one;
(3Z)-N-(3-chlorophenyl)-3-{[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-yl]methylene}-N-methyl-2-oxoindoline-5-sulfonamide; and
(3Z)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)-3-{[3,5-dimethyl-4-(3-morpholin-4-ylpropyl)-1H-pyrrol-2-yl]methylene}-1,3-dihydro-2H-indol-2-one.

### Claim 4 (depends on 1, 2)

A pharmaceutical composition, comprising a compound of Formula (I), (IV) or (VI) as claimed in claim 1 or 2 and a pharmaceutically acceptable carrier or excipient.

### Claim 5 (depends on 1, 2)

A method for the modulation of the catalytic activity of a protein kinase comprising contacting the protein kinase with a compound, or a pharmaceutically acceptable salt of a compound of Formula (I), (IV) or (VI) as claimed in claim 1 or 2.

### Claim 6 (depends on 5)

The method of claim 5, wherein the protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

### Claim 7 (depends on 1, 2)

A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt of a compound of Formula (I), (IV) or (VI) as claimed in claim 1 or 2 and a pharmaceutically acceptable carrier or excipient to the organism.

### Claim 8 (depends on 7)

The method of claim 7, wherein the protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

### Claim 9 (depends on 7)

The method of claim 7, wherein the protein kinase related disorder is selected from the group consisting of an PDGFR related disorder, a flk related disorder and a Met related disorder.

### Claim 10 (depends on 7)

The method of claim 7, wherein the protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer, gastric cancer, renal cancer, pancreatic cancer, liver cancer and gastrointestinal cancer.

### Claim 11 (depends on 7)

The method of claim 7, wherein the protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis (including pulmonary fibrosis), psoriasis, von Hippel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

### Claim 12 (depends on 7)

The method of claim 7, wherein the organism treated is a human.
